• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Stock

Elon Musk’s Neuralink raises $650 million in fresh capital

by June 3, 2025
written by June 3, 2025

Elon Musk’s brain tech startup Neuralink has closed a $650 million funding round, the company announced Monday.

ARK Invest, Founders Fund, Sequoia Capital, Thrive Capital, Lightspeed Venture Partners and other firms participated in the round, according to a press release. Neuralink said the fresh capital will help the company bring its technology to more patients and develop new devices that “deepen the connection between biological and artificial intelligence.”

Neuralink is building a brain-computer interface, or BCI, which is a system that translates brain signals into commands for external technologies.

The company’s first system, called Telepathy, involves 64 “threads” that are inserted directly into the brain. The threads are thinner than a human hair and record neural signals through 1,024 electrodes, according to Neuralink’s website.

The initial aim of the technology is to help patients with severe paralysis restore some independence. As of Monday, five patients have been implanted with Neuralink’s technology, and are able to “control digital and physical devices with their thoughts,” the release said.

Neuralink is currently carrying out four separate clinical trials around its Telepathy system.

BCIs have been studied in academia for decades, and several other companies, including Synchron, Paradromics and Precision Neuroscience, are developing their own systems.

Paradromics on Monday announced it successfully implanted its BCI in a human for the first time.

It’s not clear what devices Neuralink will look to develop next, but Musk has for years espoused grand ambitions for the brain tech startup. He has even claimed that he would be willing to get an implant himself.

One of the capabilities Musk has repeatedly highlighted is the ability to restore vision to blind patients.

Neuralink received a “Breakthrough Device” designation from the U.S. Food and Drug Administration for a device called Blindsight. This designation is granted to medical devices that have the potential to provide improved treatment for debilitating or life-threatening conditions.

In a post on his social media platform X in September, Musk said Blindsight will enable even those who have lost both eyes and their optic nerve to see.

Neuralink still has a long road ahead before it can commercialize these technologies.

This post appeared first on NBC NEWS
0 comment
0
FacebookTwitterPinterestEmail

previous post
House Dems urge GOP to condemn DHS for handcuffing Rep Nadler staffer, order Noem to testify
next post
Trump and Melania to headline power-player packed Kennedy Center opening night

related articles

Procter & Gamble to cut 7,000 jobs as...

June 6, 2025

Shein and Temu see U.S. demand plunge as...

June 6, 2025

Shein and Temu see U.S. demand plunge as...

June 5, 2025

This California startup is cleaning water and removing...

June 5, 2025

OpenAI tops 3 million paying business users, launches...

June 5, 2025

Nationwide coordinated retail crime crackdown results in hundreds...

June 4, 2025

McDonald’s Snack Wrap is officially making a permanent...

June 4, 2025

McDonald’s Snack Wrap is officially returning. Here’s when.

June 4, 2025

Peloton launching resale market for used bikes, treadmills

June 4, 2025

Dollar General is shaking off tariff fears and...

June 4, 2025
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Energy chief envisions US nuclear renaissance: restoring ‘pit’ production, localizing nuke power

    March 30, 2025
  • Trump budget bill with $4.5T in tax cuts survives key hurdle despite House GOP infighting

    February 14, 2025
  • Pentagon threatens no new limits on Ukraine weapons if North Korea joins Russia’s war

    October 30, 2024
  • Democrats don’t get a do-over just because of Biden’s debate meltdown

    July 12, 2024
  • How sustainable diaper brand Kudos is taking on industry giants — with a Target rollout

    August 6, 2024

Popular Posts

  • 1

    Secret Service admits leaning on ‘state and local partners’ after claim it ignored Trump team’s past requests

    July 21, 2024
  • 2

    Elon and Vivek should tackle US funding for this boondoogle organization and score a multimillion dollar win

    December 4, 2024
  • 3

    Forex Profit Calculator: Maximize Your Trading Potential

    July 10, 2024
  • 4

    Five more House Democrats call on Biden to drop out, third US senator

    July 19, 2024
  • 5

    Biden calls to ‘lower the temperature’ then bashes Trump in NAACP speech

    July 17, 2024

Categories

  • Economy (829)
  • Editor's Pick (4,852)
  • Investing (624)
  • Stock (790)

Latest Posts

  • Trump setting up meeting with Putin, in communication with Xi

    January 10, 2025
  • SafeMoon and Litecoin: Targets and Prices for Thursday

    October 3, 2024
  • African war-torn nation invokes Trump ‘golden age’ for minerals deal in exchange for booting violent rebels

    March 20, 2025

Recent Posts

  • 1,000 days of war in Ukraine as Zelenskyy doubles down on aerial options with ATACMS, drones and missiles

    November 19, 2024
  • Mike Johnson wins Republican support to be House speaker again after Trump endorsement

    November 13, 2024
  • HOLLYWOOD ELITES FOR HARRIS: Celebs sign on for another tired, star-filled sequel

    October 14, 2024

Editor’s Pick

  • Musk says time commitment to DOGE will ‘drop significantly’ as focus returns to Tesla

    April 23, 2025
  • Blinken arrives in Middle East to renew cease-fire negotiations in Gaza

    August 18, 2024
  • US Embassy in Thailand warns Americans of ‘violent retaliatory attacks’ risk after Uyghurs deported to China

    February 28, 2025
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock